BRGX · Bioregenx, Inc.
$0.00
+0.00 (+0.00%)
At close · Oct 23
Return incl. dividend (before tax)
Going-concern doubt
— flagged May 20, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company's ability to continue as a going concern. As reflected in the accompanying financial statements, for the three months ended March 31, 2026, the Company incurred a net loss of $(26,415), generated cash from operations of $26,629 and had a stockholder's deficit of $4,533,316 as of that date. At March 31, 2026, the Company had cash on hand in the amount of $45,806. In addition, notes payable of $522,500 are in default. As a result, management has concluded that there is substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed May 20, 2026
Market Cap
$194,315
Shares
971.58M
Volume · Oct 23
17.6K
Avg daily vol (3M)
119.2K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.00
Open$0.00
Day$0.00–0.00
52W close$0.00–0.02
Avg vol 30d115K
Short int214K · 0.0% float · 7.8d
Short vol20%
DataJan 2020–Oct 2026
Filing10-Q · May 20
Up next
filed May 20, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$1.77M
Trailing 12 months
Net income (TTM)
−$1.30M
Trailing 12 months
Revenue growth YoY
-17.3%
Year over year
Operating margin
-62.4%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$1.12M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+1.3%
Year over year · more shares
Price change (1Y)
-98.0%
Trailing year
Short interest
0.0%
Latest settlement · 7.8 days to cover
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 19.5 · elevated
Equity put/call 0.67
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−98%
below
Price vs 50-day avg
−97%
below
RSI (14)
38
neutral
MACD trend
Negative
52-week position
0%
near low
Momentum
relative strength
1-month return
−98%
trailing
6-month return
−99%
trailing
YTD return
−98%
this year
Relative strength
−105%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Flat
No 13F holder data
Insider flow
Flat
No net insider activity over 90 days
Short interest
Flat
0.02% of float · ▬ 0.0% MoM · 7.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
No 13F holder history
Squeeze score
41
elevated · 0–100
Fundamentals
Revenue growth
−21%
Y/Y
Gross margin
81%
expanding
EPS growth
+100%
Y/Y
Free cash flow
$29.9K
Balance sheet
$1.1M
net debt
Quant / Vol
risk profile
Volatility
505%
annualized · 1-yr
Max drawdown
−99%
past year
ATR
850.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−98%
Bearish
Price vs 50-day avg
−97%
Bearish
RSI (14)
38
Neutral
MACD trend
Negative
Bearish
52-week position
0%
Bearish
Market signals — smart money & positioning
No clear signal
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Flat
No 13F holder data
Insider flow
Flat
No net insider activity over 90 days
Short interest
Flat
0.02% of float · ▬ 0.0% MoM · 7.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
No 13F holder history
Price context
position in its 52-week range
Range low $0
Now $0 · 0%
Range high $0
vs 200-day avg -98%
vs 50-day avg -97%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Health Information Services — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BRGX
this stock
Bioregenx, Inc.
|
$194,315 | -98.4% | -20.8% | — | 0.0% |
|
VEEV
Veeva Systems Inc
|
$52.30B | +44.7% | +28.1% | 52.9 | 3.0% |
|
PMDIY
Pro Medicus Ltd.
|
$14.83B | -14.5% | — | — | 0.0% |
|
TEM
Tempus AI, Inc.
|
$12.20B | +14.5% | +83.4% | — | 13.9% |
|
BTSG
BrightSpring Health Services, Inc.
|
$11.89B | +60.5% | +28.2% | 36.4 | 6.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionShort & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BRGX | -95.6% | -97.5% | -98.9% | -96.4% | -98.5% |
| SPY | -0.4% | -1.5% | +5.8% | -0.4% | +11.5% |
| vs SPY | -95.1% | -96.0% | -104.7% | -96.0% | -109.9% |